Medical Device | February 23, 2022
MicroLumix’ GermPass kills Covid-19 virus in five seconds
New biotechnology product aims to be world's fastest automatic sanitary solution
New biotechnology product aims to be world's fastest automatic sanitary solution
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The grants are expected to be received over the next three years, commencing March 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
Evonik invests in start-up to improve patient recovery after open-chest surgery
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Subscribe To Our Newsletter & Stay Updated
